Home Cart Sign in  
Chemical Structure| 344458-19-1 Chemical Structure| 344458-19-1

Structure of PJ34
CAS No.: 344458-19-1

Chemical Structure| 344458-19-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

PJ34 is a specific and potent PARP1/2 inhibitor with IC50 values of 110 nM and 86 nM, respectively.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of PJ34

CAS No. :344458-19-1
Formula : C17H17N3O2
M.W : 295.34
SMILES Code : O=C1NC2=C(C3=C1C=CC=C3)C=C(NC(CN(C)C)=O)C=C2
MDL No. :MFCD17014689
InChI Key :UYJZZVDLGDDTCL-UHFFFAOYSA-N
Pubchem ID :4858

Safety of PJ34

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H317-H319
Precautionary Statements:P280-P305+P351+P338

Related Pathways of PJ34

epigenetics
DNA

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HepG2 cells 10 μM 24 h To investigate the protective effect of PJ34 against cell death induced by IK11, which it successfully mitigated by preventing ROS production and cell death. PMC3481453
H9c2 cardiomyoblasts 0.5 µM 120 minutes To investigate the protective effects of PJ34 on hypoxic-reoxygenated (HR) cardiomyoblasts. Results showed that PJ34 treatment significantly reduced oxidative stress and PARP-1 activity, attenuated NAD+ and ATP depletion, and improved mitochondrial function. Furthermore, PJ34 treatment significantly improved the survival of HR cells, reduced necrosis and apoptosis, and shifted apoptosis from a caspase-independent to a caspase-dependent pathway. PMC11136184
Endothelial Progenitor Cells (EPCs) 2 μM 6 hours PJ34 treatment preserved intracellular NAD+ levels by inhibiting PARP1 activation, reducing PAR synthesis, increasing SIRT1 activity, decreasing p53 acetylation, and improving the function of stress-induced premature aging EPCs PMC6107962
MDA-MB-231 cells 10 µM 24 hours To evaluate the effects of PJ-34 on cell proliferation and oxidative stress, results showed that DHHC3 ablation enhanced the anti-proliferative effects and oxidative stress induced by PJ-34. PMC8751980
BT-549 cells 10 µM 24 hours To evaluate the effects of PJ-34 on oxidative stress, results showed that DHHC3 ablation enhanced the oxidative stress induced by PJ-34. PMC8751980
PC3 cells 10 µM 24 hours To evaluate the effects of PJ-34 on oxidative stress, results showed that DHHC3 ablation enhanced the oxidative stress induced by PJ-34. PMC8751980

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice transient focal cerebral ischemia Intraperitoneal injection 1.25–25 mg/kg once before and once after ischemia PJ34 showed a significant inhibitory effect on inflammatory markers and reduced cerebral infarct volume. PMC1629400
Mice Type 2 diabetic mouse model Intraperitoneal injection 30 mg/kg 3 or 6 doses over 24 hours PJ34 significantly reduced PARP activity, decreased muscle fiber injury, increased metabolic activity, and reduced GAPDH nuclear translocation and ribosylation. PMC3773522
Mice Murine model of type 2 diabetes Intraperitoneal injection 30 mg/kg At 5 minutes prior to reperfusion, 15 minutes, 2 hours (3 dose PJ34 therapy) or additional 6 hours, 12 hours and 18 hours reperfusion (total 6 dose PJ34 therapy) PJ34 reduced tissue injury in acute ischemia-reperfusion injury, significantly preserved GAPDH activity, reduced PARP activity and GAPDH nuclear translocation. PMC3773522

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.39mL

0.68mL

0.34mL

16.93mL

3.39mL

1.69mL

33.86mL

6.77mL

3.39mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories